SGLT2 inhibition: a new era in renoprotective medicine?

Research output: Contribution to journal › Comment/Letter to the editor › Academic

7 Citations (Scopus)

Original language	English
Pages (from-to)	569-571
Number of pages	3
Journal	The Lancet Diabetes and Endocrinology
Volume	5
Issue number	8
DOIs	https://doi.org/10.1016/S2213-8587(17)30222-X
Publication status	Published - 1 Aug 2017

Access to Document

@article{9c78e950455240bda1d55750da03c8fc,

title = "SGLT2 inhibition: a new era in renoprotective medicine?",

author = "Muskiet, {Marcel H.A.} and Heerspink, {Hiddo J.L.} and {van Raalte}, {Dani{\"e}l H.}",

year = "2017",

month = aug,

day = "1",

doi = "https://doi.org/10.1016/S2213-8587(17)30222-X",

language = "English",

volume = "5",

pages = "569--571",

journal = "The Lancet Diabetes and Endocrinology",

issn = "2213-8587",

publisher = "Elsevier BV",

number = "8",

}

TY - JOUR

T1 - SGLT2 inhibition

T2 - a new era in renoprotective medicine?

AU - Muskiet, Marcel H.A.

AU - Heerspink, Hiddo J.L.

AU - van Raalte, Daniël H.

PY - 2017/8/1

Y1 - 2017/8/1

UR - http://www.scopus.com/inward/record.url?scp=85021282260&partnerID=8YFLogxK

U2 - https://doi.org/10.1016/S2213-8587(17)30222-X

DO - https://doi.org/10.1016/S2213-8587(17)30222-X

M3 - Comment/Letter to the editor

SN - 2213-8587

VL - 5

SP - 569

EP - 571

JO - The Lancet Diabetes and Endocrinology

JF - The Lancet Diabetes and Endocrinology

IS - 8

ER -